Altre lingue NewAmsterdam Pharma Company N.V. Nasdaq

Azioni

NAMS

NL00150012L7

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 21/06/2024			Variaz. 5gg	Var. 1 gen.
18,02 ^USD	+4,59%		-6,10%	+61,33%

11/06	NewAmsterdam Pharma ottiene un altro brevetto statunitense che estende la protezione della proprietà intellettuale di obicetrapib fino a luglio 2043	MT
10/06	Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043	11/06
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office	11/06
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/06
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29/05
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June	29/05
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings	21/05
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	09/05
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	09/05
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	02/05
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	09/04
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	01/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NewAmsterdam Pharma Company N.V. Nasdaq

Azioni

NAMS

NL00150012L7

Altre lingue

Filtri